MLYS Stock Summary and Trading Ideas (Mineralys Therapeutics | NASDAQ:MLYS)

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Mineralys Therapeutics trades on the NASDAQ stock market under the symbol MLYS.

As of March 5, 2025, MLYS stock price climbed to $10.01 with 179,972 million shares trading.

MLYS has a beta of 2.16, meaning it tends to be more sensitive to market movements. MLYS has a correlation of 0.21 to the broad based SPY ETF.

MLYS has a market cap of $498.85 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that MLYS belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

MLYS has underperformed the market in the last year with a return of -33.2%, while the SPY ETF gained +15.2%. In the last 3 month period, MLYS fell short of the market, returning -20.2%, while SPY returned -3.7%. However, in the most recent 2 weeks MLYS has outperformed the stock market by returning +4.3%, while SPY returned -4.6%.

MLYS support price is $9.33 and resistance is $10.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLYS shares will trade within this expected range on the day.